PB Fintech runs an asset-light, digital-first distribution model for insurance and credit. It does not underwrite insurance or carry lending risk on its balance sheet. Revenue comes mainly from commissions and fees across B2C direct, B2B2C (PB Partners POSP network) and corporate channels.

New Initiatives are PB Partners (1.13 lakh active partners, ₹561 Cr revenue in Q1), Policybazaar for Business, Policybazaar UAE (profitable in FY26 and Q1 FY27) and PB Connect, whose wholesale arm has been stopped. Management targets group PAT of about ₹1,000 Cr in FY27. Management says life and general insurance contribute roughly equally to core revenue, which matters for the regulatory impact below.

Quality flags: PAT includes about ₹370 Cr of other income (treasury); the effective tax rate was 5% in FY26 against a statutory 25%; operating cash flow has lagged profit because receivables grow with revenue. FY26 equity is about ₹7,312 Cr, borrowings ₹360 Cr, investments ₹3,211 Cr. ROE is about 10%. Q1 is seasonally softer than Q4, so Q1 FY27 PAT fell 38% QoQ.

We anchor FY28E earnings to broker sensitivities published after the draft rules: pre-regulation FY28E PAT of about ₹1,420 Cr (back-solved from Motilal Oswal’s 46% cut and 73x P/E math), a 12% earnings hit (Jefferies, for a 10% commission-rate cut), a 30% hit (Motilal, with 20% cost cuts) and a 46% hit (Motilal, no cost response). Operating FCF is derived after stripping other income, with cash conversion rising from 70% to 85% and tax normalising towards 25%. Treasury of about ₹2,850 Cr (investments less borrowings) is added separately.

We apply a forward P/E to FY28E EPS and discount one year at 12%. Fair multiples are 55x (bull), 42x (base) and 32x (bear), reflecting roughly 25% EPS growth tempered by regulatory uncertainty.

We did not build a listed-peer multiple table: comparable Indian insurance distributors with verified, current multiples are scarce, so the sector P/E and broker multiples above serve as cross-checks.

Book value is about ₹158 per share (₹7,312 Cr over ~46.3 Cr shares). The balance sheet is nearly debt-free, but most assets are treasury and receivables; the platform, brand and customer base are not carried at value. NAV is a floor reference only. At ₹994 the stock trades at about 6.3x book.

TTM EBIT is about ₹463 Cr (EBITDA ₹606 Cr less depreciation ₹143 Cr). Adding back roughly half of the heavy growth marketing (Q1 FY27 A&P was ₹379 Cr, up 50%) gives normalised pre-tax earnings near ₹900 Cr. At 25% tax and a 12% rate, EPV of operations is about ₹5,600 Cr; adding treasury of ₹2,850 Cr gives about ₹8,450 Cr, or ₹183 per share. EPV values zero growth, so it frames how much of the price rests on future expansion: about 80%.

Segment EBITDA for FY28E is estimated from the scenario group EBITDA, with New Initiatives near break-even and Paisabazaar at about ₹100 Cr. These segment splits are our estimates, not company disclosures.

Probability-weighted SOTP (30/45/25): ₹801. PB Healthcare and the possible insurance-manufacturing or MGA route are treated as unpriced option value.

Weights: DCF 35%, relative 25%, SOTP 25%, EPV 10%, NAV 5%. The blended fair value is about ₹545 (bear ₹327, base ₹534, bull ₹825).

At ₹994 the stock sits in the Exit zone of our framework.

Renewal and trail income (₹1,003 Cr rolling, +38%) builds a recurring base that sits partly outside new-business commission caps. Other levers: health and term protection growth (new health +59% in Q1), PB Partners reach in Tier 2/3 (78% of its premium), UAE scale-up, Paisabazaar’s return to growth (core revenue +25%), AI-led conversion and servicing, and a possible move into MGA, credit-life or own-insurer models. Management plans to slow hiring and trim marketing near term.

Foreign investors have trimmed every quarter while mutual funds lifted their stake from about 16% to 28% in a year, so domestic funds absorbed the supply. Their positions now carry large mark-to-market losses, and that crowding can cut both ways in a falling market. The company has no promoter; the founder holds about 3.3%. Figures come from third-party data, may lag the live quarter, and the two largest lines are reported identically by the source; verify against BSE/NSE shareholding filings for scheme-wise and FPI-wise detail.